Mitoxantrone-loaded superparamagnetic iron oxide nanoparticles as drug carriers for cancer therapy: Uptake and toxicity in primary human tubular epithelial cells

References

• Albanese A, Tang PS, Chan WC. 2012. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 14:1–16
   PubMed Web of Science ®Google Scholar
• Alberts DS, Peng YM, Leigh S, Davis TP, Woodward DL. 1985. Disposition of mitoxantrone in cancer patients. Cancer Res 45:1879–84
   PubMed Web of Science ®Google Scholar
• Amstad E, Textor M, Reimhult E. 2011. Stabilization and functionalization of iron oxide nanoparticles for biomedical applications. Nanoscale 3:2819–43
   PubMed Web of Science ®Google Scholar
• An G, Morris ME. 2012. A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding. Aaps J 14:352–64
   PubMed Web of Science ®Google Scholar
• Bernd H, De Kerviler E, Gaillard S, Bonnemain B. 2009. Safety and tolerability of ultrasmall superparamagnetic iron oxide contrast agent: comprehensive analysis of a clinical development program. Invest Radiol 44:336–42
   PubMed Web of Science ®Google Scholar
• Bidaud-Meynard A, Arma D, Taouji S, Laguerre M, Dessolin J, Rosenbaum J, et al. 2013. A novel small-molecule screening strategy identifies mitoxantrone as a RhoGTPase inhibitor. Biochem J 450:55–62
   PubMed Web of Science ®Google Scholar
• Cocco E, Marrosu MG. 2014. The current role of mitoxantrone in the treatment of multiple sclerosis. Expert Rev Neurother 14:607–16
   PubMed Web of Science ®Google Scholar
• Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. 1995. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92:9363–7
   PubMed Web of Science ®Google Scholar
• Ehninger G, Schuler U, Proksch B, Zeller KP, Blanz J. 1990. Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet 18:365–80
   PubMed Web of Science ®Google Scholar
• Feofanov A, Sharonov S, Fleury F, Kudelina I, Nabiev I. 1997. Quantitative confocal spectral imaging analysis of mitoxantrone within living K562 cells: intracellular accumulation and distribution of monomers, aggregates, naphtoquinoxaline metabolite, and drug-target complexes. Biophys J 73:3328–36
   PubMed Web of Science ®Google Scholar
• Gupta AK, Gupta M. 2005. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26:3995–4021
   PubMed Web of Science ®Google Scholar
• Homolya L, Orban TI, Csanady L, Sarkadi B. 2011. Mitoxantrone is expelled by the ABCG2 multidrug transporter directly from the plasma membrane. Biochim Biophys Acta 1808:154–63
   PubMed Web of Science ®Google Scholar
• Hu OY, Chang SP, Law CK, Jian JM, Chen KY. 1992. Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma. Cancer 69:847–53
   PubMed Web of Science ®Google Scholar
• Ichijima Y, Sakasai R, Okita N, Asahina K, Mizutani S, Teraoka H. 2005. Phosphorylation of histone H2AX at M phase in human cells without DNA damage response. Biochem Biophys Res Commun 336:807–12
   PubMed Web of Science ®Google Scholar
• Janko C, Durr S, Munoz LE, Lyer S, Chaurio R, Tietze R, et al. 2013. Magnetic drug targeting reduces the chemotherapeutic burden on circulating leukocytes. Int J Mol Sci 14:7341–55
   PubMed Web of Science ®Google Scholar
• Jeng HA, Swanson J. 2006. Toxicity of metal oxide nanoparticles in mammalian cells. J Environ Sci Health a Tox Hazard Subst Environ Eng 41:2699–11
   PubMed Web of Science ®Google Scholar
• Keller C, Kroening S, Zuehlke J, Kunath F, Krueger B, Goppelt-Struebe M. 2012. Distinct mesenchymal alterations in N-cadherin and e-cadherin positive primary renal epithelial cells. PLoS One 7:e43584
   PubMed Web of Science ®Google Scholar
• Kriz W, LeHir M. 2005. Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int 67:404–19
   PubMed Web of Science ®Google Scholar
• Kroening S, Neubauer E, Wullich B, Aten J, Goppelt-Struebe M. 2010. Characterization of connective tissue growth factor expression in primary cultures of human tubular epithelial cells: modulation by hypoxia. Am J Physiol Renal Physiol 298:F796–806
   PubMed Web of Science ®Google Scholar
• Laurent S, Saei AA, Behzadi S, Panahifar A, Mahmoudi M. 2014. Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges. Expert Opin Drug Deliv 11:1449–70
   PubMed Web of Science ®Google Scholar
• Lyer S, Tietze R, Jurgons R, Struffert T, Engelhorn T, Schreiber E, et al. 2010. Visualisation of tumour regression after local chemotherapy with magnetic nanoparticles – a pilot study. Anticancer Res 30:1553–7
   PubMed Web of Science ®Google Scholar
• McClendon AK, Osheroff N. 2007. DNA topoisomerase II, genotoxicity, and cancer. Mutat Res 623:83–97
   PubMed Web of Science ®Google Scholar
• McManus KJ, Hendzel MJ. 2005. ATM-dependent DNA damage-independent mitotic phosphorylation of H2AX in normally growing mammalian cells. Mol Biol Cell 16:5013–25
   PubMed Web of Science ®Google Scholar
• Nagai J, Takano M. 2014. Entry of aminoglycosides into renal tubular epithelial cells via endocytosis-dependent and endocytosis-independent pathways. Biochem Pharmacol 90:331–7
   PubMed Web of Science ®Google Scholar
• Poettler M, Hofman S, Durr S, Wiest I, Zaloga J, Jeschke U, et al. 2014. Effect of BSA-coated superparamagnetic iron oxide nanoparticles on granulosa cells. Anticancer Res 34:6843–4
   Web of Science ®Google Scholar
• Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. 1998. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273:5858–68
   PubMed Web of Science ®Google Scholar
• Saito A, Sato H, Iino N, Takeda T. 2010. Molecular mechanisms of receptor-mediated endocytosis in the renal proximal tubular epithelium. J Biomed Biotechnol 2010:403272
   PubMed Web of Science ®Google Scholar
• Savaraj N, Lu K, Manuel V, Loo TL. 1982. Pharmacology of mitoxantrone in cancer patients. Cancer Chemother Pharmacol 8:113–17
   PubMed Web of Science ®Google Scholar
• Scott LJ, Figgitt DP. 2004. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs 18:379–96
   PubMed Web of Science ®Google Scholar
• Soenen SJ, Nuytten N, De Meyer SF, De Smedt SC, De Cuyper M. 2010. High intracellular iron oxide nanoparticle concentrations affect cellular cytoskeleton and focal adhesion kinase-mediated signaling. Small 6:832–42
   PubMed Web of Science ®Google Scholar
• Tietze R, Lyer S, Durr S, Struffert T, Engelhorn T, Schwarz M, et al. 2013. Efficient drug-delivery using magnetic nanoparticles-biodistribution and therapeutic effects in tumour bearing rabbits. Nanomedicine 9:961–71
   PubMed Web of Science ®Google Scholar
• Toh YM, Li TK. 2011. Mitoxantrone inhibits HIF-1α expression in a topoisomerase II-independent pathway. Clin Cancer Res 17:5026–37
   PubMed Web of Science ®Google Scholar
• Wahajuddin Arora S. 2012. Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int J Nanomedicine 7:3445–71
   PubMed Web of Science ®Google Scholar
• Winer JL, Liu CY, Apuzzo ML. 2012. The use of nanoparticles as contrast media in neuroimaging: a statement on toxicity. World Neurosurg 78:709–11
   PubMed Web of Science ®Google Scholar
• Zaloga J, Janko C, Nowak J, Matuszak J, Knaup S, Eberbeck D, et al. 2014. Development of a lauric acid/albumin hybrid iron oxide nanoparticle system with improved biocompatibility. Int J Nanomedicine 9:4847–66
   PubMed Web of Science ®Google Scholar
• Zhao H, Halicka HD, Traganos F, Jorgensen E, Darzynkiewicz Z. 2010. New biomarkers probing depth of cell senescence assessed by laser scanning cytometry. Cytometry a 77:999–1007
   PubMed Web of Science ®Google Scholar
• Zhao H, Rybak P, Dobrucki J, Traganos F, Darzynkiewicz Z. 2012. Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide. Cytometry a 81:45–51
   PubMed Web of Science ®Google Scholar
• Zuehlke J, Ebenau A, Krueger B, Goppelt-Struebe M. 2012. Vectorial secretion of CTGF as a cell-type specific response to LPA and TGF-β in human tubular epithelial cells. Cell Commun Signal 10:doi:10.1186/1478-811X-10-25
   PubMed Web of Science ®Google Scholar